Development of a Tritiated Agonist Radioligand for the D2 Receptor

Information

  • Research Project
  • 8775067
  • ApplicationId
    8775067
  • Core Project Number
    R43OD020186
  • Full Project Number
    1R43OD020186-01A1
  • Serial Number
    020186
  • FOA Number
    PA-13-234
  • Sub Project Id
  • Project Start Date
    9/1/2014 - 10 years ago
  • Project End Date
    10/31/2015 - 9 years ago
  • Program Officer Name
    CONTRERAS, MIGUEL A.
  • Budget Start Date
    9/1/2014 - 10 years ago
  • Budget End Date
    10/31/2015 - 9 years ago
  • Fiscal Year
    2014
  • Support Year
    01
  • Suffix
    A1
  • Award Notice Date
    9/1/2014 - 10 years ago

Development of a Tritiated Agonist Radioligand for the D2 Receptor

DESCRIPTION (provided by applicant): The goal of this project is to develop a novel agonist radioligand for evaluating the proportion of D2 receptors in the high state. The D2high receptor is thought to be the functional form of the D2 receptor to which endogenous dopamine binds. An agonist radioligand should be more sensitive to endogenous DA levels than antagonist radioligands since, unlike antagonists, agonist radioligands bind preferentially to the receptor in its high affinity state. Thus, agonist radioligands have the potential to elucidate more detailed information on receptor subtype activity as a function of disease as well as DA system activity as a whole. The majority of available radioligands are based on D2 antagonists and, as such, do not specifically target the D2high state. Among the commercially available agonist ligands, none possess high selectivity for D2 over D3. In contrast, fluoroaporphines, which are the focus of this project, are D2 receptor agonists that specifically and selectively target D2high receptors. The objective of this project is, therefore, to develop 3H-labeled fluoroaporphines as radioligands for in vitro binding studies and for autoradiography to aid in the evaluation and study of the role of the D2high receptor function in the brain.

IC Name
OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH
  • Activity
    R43
  • Administering IC
    OD
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    148426
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    351
  • Ed Inst. Type
  • Funding ICs
    OD:148426\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    NATURAL PHARMACIA INTERNATIONAL, INC.
  • Organization Department
  • Organization DUNS
    926458290
  • Organization City
    BURLINGTON
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    018034990
  • Organization District
    UNITED STATES